Dyne Therapeutics (DYN)
(Delayed Data from NSDQ)
$26.00 USD
+0.05 (0.19%)
Updated May 10, 2024 04:00 PM ET
After-Market: $25.76 -0.24 (-0.92%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Balance Sheet
Fiscal Year End for Dyne Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 123 | 256 | 377 | 345 | 15 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 10 | 6 | 4 | 0 |
Total Current Assets | 129 | 266 | 382 | 349 | 15 |
Net Property & Equipment | 5 | 6 | 5 | 2 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 2 | 2 | 2 | 0 |
Total Assets | 165 | 306 | 426 | 353 | 16 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 23 | 5 | 4 | 3 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 23 | 18 | 21 | 8 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 51 | 28 | 29 | 11 | 2 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 74 | 54 | 57 | 11 | 2 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 27 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 724 | 650 | 597 | 422 | 6 |
Retained Earnings | -633 | -397 | -228 | -79 | -20 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 91 | 252 | 368 | 342 | 14 |
Total Liabilities & Shareholder's Equity | 165 | 306 | 426 | 353 | 16 |
Total Common Equity | 91 | 252 | 368 | 342 | -13 |
Shares Outstanding | 61.40 | 52.10 | 51.50 | 45.40 | NA |
Book Value Per Share | 1.49 | 4.84 | 7.15 | 7.54 | 0.00 |
Fiscal Year End for Dyne Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 454 | 123 | 158 | 208 | 238 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | 35 | 6 | 10 | 5 | 11 |
Total Current Assets | 488 | 129 | 168 | 213 | 249 |
Net Property & Equipment | 5 | 5 | 5 | 5 | 6 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 2 | 2 | 2 | 2 |
Total Assets | 522 | 165 | 205 | 251 | 289 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 23 | 4 | 3 | 9 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | 10 | 23 | 21 | 13 | 8 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | 22 | 51 | 30 | 20 | 22 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | 44 | 74 | 53 | 45 | 47 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,176 | 724 | 718 | 713 | 683 |
Retained Earnings | -698 | -633 | -566 | -506 | -441 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 478 | 91 | 152 | 207 | 242 |
Total Liabilities & Shareholder's Equity | 522 | 165 | 205 | 251 | 289 |
Total Common Equity | 100,477 | 91 | 152 | 207 | 242 |
Shares Outstanding | 86.10 | 61.40 | 61.30 | 58.30 | 58.30 |
Book Value Per Share | 1,166.98 | 1.49 | 2.48 | 3.55 | 4.15 |